113 related articles for article (PubMed ID: 12138369)
1. Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension.
Martin I; Humbert M; Marfaing-Koka A; Capron F; Wolf M; Meyer D; Simonneau G; Anglés-Cano E
Blood Coagul Fibrinolysis; 2002 Jul; 13(5):417-22. PubMed ID: 12138369
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension.
Huber K; Beckmann R; Frank H; Kneussl M; Mlczoch J; Binder BR
Am J Respir Crit Care Med; 1994 Oct; 150(4):929-33. PubMed ID: 7921465
[TBL] [Abstract][Full Text] [Related]
3. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Montemurro P; Conese M; Altomare DF; Memeo V; Colucci M; Semeraro N
Int J Clin Lab Res; 1995; 25(4):195-200. PubMed ID: 8788547
[TBL] [Abstract][Full Text] [Related]
4. Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.
Maris NA; de Vos AF; Bresser P; van der Zee JS; Jansen HM; Levi M; van der Poll T
Crit Care Med; 2007 Jan; 35(1):57-63. PubMed ID: 17080003
[TBL] [Abstract][Full Text] [Related]
5. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
[TBL] [Abstract][Full Text] [Related]
6. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
7. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: trends in two forms of lung injury.
Idell S; James KK; Coalson JJ
Crit Care Med; 1992 Oct; 20(10):1431-40. PubMed ID: 1395665
[TBL] [Abstract][Full Text] [Related]
10. Relationship between endothelial function and fibrinolysis in early hypertension.
Tomiyama H; Kimura Y; Mitsuhashi H; Kinouchi T; Yoshida H; Kushiro T; Doba N
Hypertension; 1998 Jan; 31(1 Pt 2):321-7. PubMed ID: 9453323
[TBL] [Abstract][Full Text] [Related]
11. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Kotani I; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Thromb Res; 1995 Mar; 77(6):493-504. PubMed ID: 7624837
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
13. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension.
Altman R; Scazziota A; Rouvier J; Gurfinkel E; Favaloro R; Perrone S; Fareed J
Clin Cardiol; 1996 Jul; 19(7):549-54. PubMed ID: 8818435
[TBL] [Abstract][Full Text] [Related]
14. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
Xiao W; Tong WL; Ma DD
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1996 Nov; 241(3):840-8. PubMed ID: 8944773
[TBL] [Abstract][Full Text] [Related]
16. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
[TBL] [Abstract][Full Text] [Related]
17. Monocytes modulate the fibrinolytic balance of endothelial cells.
Funayama H; Sakata Y; Kitagawa S; Ikeda U; Takahashi M; Masuyama J; Mimuro J; Matsuda M; Shimada K
Thromb Res; 1997 Mar; 85(5):377-85. PubMed ID: 9076895
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury.
Horton MR; Olman MA; Noble PW
Chest; 1999 Jul; 116(1 Suppl):17S. PubMed ID: 10424564
[No Abstract] [Full Text] [Related]
19. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.
Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC
Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659
[TBL] [Abstract][Full Text] [Related]
20. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
